Research Article
Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study
Table 3
Unadjusted summaries of measured variables pre- and posttreatment.
| | | Placebo () | Atorvastatin () | | | Pre | Post | % | Pre | Post | % |
| | oxLDLβ 2GPI u/L | | | | | | | | Mean ± SD | 2.6 ± 0.5 | 2.9 ± 0.5 | 11.5% | 2.6 ± 0.7 | 1.9 ± 0.5 | −26.9% | | Median ± IQR | 2.6 ± 0.7 | 2.8 ± 1.0 | 7.7% | 2.8 ± 1.1 | 1.9 ± 0.7 | −32.1% | | CRP µg/mL | | | | | | | | Mean ± SD | 3.0 ± 2.7 | 3.4 ± 2.3 | 13.3% | 6.6 ± 8.4 | 1.9 ± 1.2 | −71.2% | | Median ± IQR | 2.4 ± 2.7 | 2.8 ± 3.5 | 16.7% | 2.9 ± 6.0 | 2.0 ± 2.0 | −31.0% | | SAA µg/mL | | | | | | | | Mean ± SD | 13.5 ± 9.5 | 3.8 ± 2.4 | −71.9% | 14.5 ± 11.2 | 5.3 ± 4.8 | −63.4% | | Median ± IQR | 16.2 ± 15.8 | 3.4 ± 4.9 | −79.0% | 9.9 ± 20.5 | 3.3 ± 5.2 | −66.7% | | µM | | | | | | | | Mean ± SD | 31.6 ± 25.0 | 27.0 ± 16.9 | −14.6% | 20.2 ± 10.2 | 18.9 ± 9.6 | −6.4% | | Median ± IQR | 21.8 ± 31.2 | 23.6 ± 24.9 | 8.3% | 20.4 ± 19.0 | 17.6 ± 12.5 | −13.7% | | µM | | | | | | | | Mean ± SD | 9.2 ± 4.9 | 9.6 ± 4.9 | 4.3% | 13.1 ± 6.4 | 11.3 ± 4.2 | −13.7% | | Median ± IQR | 6.6 ± 9.1 | 9.1 ± 4.4 | 37.9% | 10.5 ± 10.0 | 10.5 ± 5.2 | 0.0% | | NT Nm | | | | | | | | Mean ± SD | 557.2 ± 1729.4 | 307.2 ± 673.1 | −44.9% | 266.6 ± 593.5 | 143.1 ± 177.1 | −46.3% | | Median ± IQR | 15.9 ± 47.1 | 111.1 ± 151.8 | 598.7% | 18.7 ± 84.0 | 78.5 ± 164.2 | 319.8% | | TG mmol/L | | | | | | | | Mean ± SD | 1.23 ± 0.61 | 1.17 ± 0.47 | −4.9% | 1.26 ± 0.78 | 1.07 ± 0.62 | −15.1% | | Median ± IQR | 1.15 ± 1.08 | 1.10 ± 0.90 | −4.3% | 1.00 ± 1.08 | 0.95 ± 0.95 | −5.0% | | CHO mmol/L | | | | | | | | Mean ± SD | 5.43 ± 0.96 | 5.50 ± 1.02 | 1.3% | 4.36 ± 1.21 | 3.23 ± 0.62 | −25.9% | | Median ± IQR | 5.15 ± 1.55 | 5.70 ± 1.35 | 10.7% | 4.30 ± 1.70 | 3.35 ± 0.90 | −22.1% | | LDL mmol/L | | | | | | | | Mean ± SD | 2.95 ± 0.67 | 3.16 ± 0.53 | 7.1% | 2.55 ± 1.05 | 1.49 ± 0.57 | −41.6% | | Median ± IQR | 2.80 ± 1.20 | 3.10 ± 1.00 | 10.7% | 2.70 ± 1.10 | 1.40 ± 0.78 | −48.1% | | HDL mmol/L | | | | | | | | Mean ± SD | 1.86 ± 0.58 | 1.81 ± 0.46 | −2.7% | 1.20 ± 0.27 | 1.28 ± 0.21 | 6.7% | | Median ± IQR | 1.75 ± 0.55 | 1.70 ± 0.65 | −2.9% | 1.25 ± 0.45 | 1.30 ± 0.35 | 4.0% | | PON U/L | | | | | | | | Mean ± SD | 101.36 ± 16.38 | 92.65 ± 23.18 | −8.6% | 78.31 ± 17.52 | 94.44 ± 18.40 | 20.6% | | Median ± IQR | 106.80 ± 13.22 | 103.38 ± 45.53 | −3.2% | 78.06 ± 30.03 | 104.52 ± 33.76 | 33.9% | | PON/HDL | | | | | | | | Mean ± SD | 58.29 ± 19.43 | 55.80 ± 16.21 | −4.3% | 70.92 ± 28.20 | 79.26 ± 21.46 | 11.8% | | Median ± IQR | 52.85 ± 29.09 | 59.46 ± 21.90 | 12.5% | 62.88 ± 28.25 | 78.96 ± 32.08 | 25.6% | | IMT CC mm | | | | | | | | Mean ± SD | 0.058 ± 0.013 | 0.057 ± 0.014 | −1.7% | 0.057 ± 0.010 | 0.059 ± 0.010 | 3.5% | | Median ± IQR | 0.055 ± 0.018 | 0.050 ± 0.020 | −9.1% | 0.058 ± 0.015 | 0.060 ± 0.015 | 3.4% |
|
|
%: percentage difference; oxLDLβ 2GPI: oxidised low density lipoprotein-beta 2-glycoprotein-1 complex; CRP: C-reactive protein; SAA: serum amyloid A; : nitrate; : nitrite; NT: nitrotyrosine; TG: triglycerides; CHO: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; PON: paraoxonase; IMT CC: intima media thickness of common carotid artery; SD: standard deviation; IQR: interquartile range.
|
